Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

BackgroundPatients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial that investigated adding palbociclib (PAL) for thi...

Full description

Bibliographic Details
Main Authors: Katya Galactionova, Sibylle Loibl, Paola Salari, Frederik Marmé, Miguel Martin, Michael Untch, Hervé R. Bonnefoi, Sung-Bae Kim, Harry D. Bear, Nicole McCarthy, Karen A. Gelmon, José A. García-Sáenz, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Hope S. Rugo, Michael Gnant, Andreas Makris, Nicole Burchardi, Matthias Schwenkglenks
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
Penelope-B
Palbociclib
CDKi
(postneo)adjuvant
early breast cancer
cost-effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.886831/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.886831/full

Similar Items